только для медицинских специалистов

Консультант врача

Электронная медицинская библиотека

Раздел 4 / 10
Страница 2 / 2

Список литературы

 

  1. Abdelgawad E.A. et al. Magnetic resonance imaging (MRI) volumetry in children with nonlesional epilepsy, does it help? // Egypt. J. Radiol. Nucl. Med. Springer Open, 2021. Vol. 52, № 35. P. 1–11.
  2. Bernasconi N., Wang I. Emerging Trends in Neuroimaging of Epilepsy // Epilepsy Curr. SAGE Publications Ltd, 2021. Vol. 21, № 2. P. 79–82.
  3. Tranvinh E. et al. Imaging evaluation of the adult presenting with new-onset seizure // Am. J. Roentgenol. American Roentgen Ray Society, 2019. Vol. 212, № 1. P. 15–25.
  4. Евстигнеев В.В., Сакович Р.А., Кистень О.В. Результаты первого опыта использования позитронно-эмиссионной томографии в Республике Беларусь для диагностики эпилепсии // Международный неврологический журнал. ФЛП «Заславский Александр Юрьевич», 2017. Vol. 3, № 89. P. 110–116.
  5. Tang Y. Et al. FDG-PET Profiles of Extratemporal Metabolism as a Predictor of Surgical Failure in Temporal Lobe Epilepsy // Front. Med. Frontiers Media S.A., 2020. Vol. 7.
  6. Chassoux F. et al. 18F-FDG-PET patterns of surgical success and failure in mesial temporal lobe epilepsy // Neurology. Lippincott Williams and Wilkins, 2017. Vol. 88, № 11. P. 1045–1053.
  7. Stefanski A. et al. Clinical sequencing yield in epilepsy, autism spectrum disorder, and intellectual disability: A systematic review and meta-analysis // Epilepsia. Blackwell Publishing Inc., 2021. Vol. 62, № 1. P. 143–151.
  8. Аношкин К.И., Карандашева К.О., Танас А.С., Бесонова Л.А., Демина Н.А., Петухова М.С., Анисимова И.В., Залетаев Д.В., Стрельников В.В. Медицинская технология комплексной ДНК-диагностики туберозного склероза. Медицинская генетика, 2018, Том 17 №8, стр. 32-37
  9. Ritter D.M., Holland K. Genetic Testing in Epilepsy // Semin. Neurol. Thieme Medical Publishers, Inc., 2020. Vol. 40, № 6. P. 730–738.
  10. Anney R.J.L. et al. Genetic determinants of common epilepsies: A meta-analysis of genome- wide association studies // Lancet Neurol. Lancet Publishing Group, 2014. Vol. 13, № 9. P. 893–903.
  11. Singh R. et al. Chromosomal abnormalities and epilepsy: A review for clinicians and gene hunters // Epilepsia. Epilepsia, 2002. Vol. 43, № 2. P. 127–140.
  12. Coppola A. et al. Diagnostic implications of genetic copy number variation in epilepsy plus // Epilepsia. Blackwell Publishing Inc., 2019. Vol. 60, № 4. P. 689–706.
  13. Berkovic S.F. et al. The Epilepsy Genetics Initiative: Systematic reanalysis of diagnostic exomes increases yield // Epilepsia. Blackwell Publishing Inc., 2019. Vol. 60, № 5. P. 797–806.
  14. Bonello D., Camilleri F., Calleja-AgiusJ. Angelman Syndrome: Identification and Management Neonatal Netw. 2017 May 1;36(3):142-151.
  15. Байдакова Г.В., Иванова Т.А., Захарова Е.Ю., Кокорина О.С. Роль тандемной масс- спектрометрии в диагностике наследственных болезней обмена веществ // РЖДГиО. 2018. №3.
  16. Campistol J. Epilepsy in Inborn Errors of Metabolism With Therapeutic Options // Semin. Pediatr. Neurol. W.B. Saunders, 2016. Vol. 23, № 4. P. 321–331.
  17. van Karnebeek CD, Stockler S. Treatable inborn errors of metabolism causing intellectual disability: a systematic literature review. Mol Genet Metab. 2012 Mar;105(3):368-81. doi: 10.1016/j.ymgme.2011.11.191. Epub 2011 Nov 30
  18. Wilmshurst J.M. et al. Summary of recommendations for the management of infantile seizures: Task Force Report for the ILAE Commission of Pediatrics // Epilepsia. Blackwell Publishing Inc., 2015. Vol. 56, № 8. P. 1185–1197.
  19. Gillis L., Kaye E. Diagnosis and management of mitochondrial diseases // Pediatric Clinics of North America. Pediatr Clin North Am, 2002. Vol. 49, № 1. P. 203–219.
  20. Mulley GC, Mefford H.C. Epilepsy and the new cytogenetics. Epilepsia2011 Mar;52(3):423-32.
  21. Fraser L.K. et al. Rising national prevalence of life-limiting conditions in children in England // Pediatrics. Pediatrics, 2012. Vol. 129, № 4.
  22. Hain R. et al. Paediatric palliative care: Development and pilot study of a “Directory” of life- limiting conditions // BMC Palliat. Care. BMCPalliatCare, 2013. Vol. 12, № 1.
  23. Вишняков Н.И. etal. Медико-социальные проблемы хосписов в педиатрической практике Санкт-Петербурга // Педиатр. Общество с ограниченной ответственностью «Эко-Вектор», 2014. Vol. 5, № 1.
  24. Dallas J., Englot D.J., Naftel R.P. Neurosurgical approaches to pediatric epilepsy: Indications, techniques, and outcomes of common surgical procedures // Seizure. W.B. Saunders Ltd, 2020. Vol. 77. P. 76–85.
  25. Лебедев К.Э., Маматханов М.Р. Показания и общие принципы хирургического лечения эпилепсии (обзор) // Нейрохирургия и неврология детского возраста. Федеральное государственное учреждение" Российский научно-исследовательский …, 2016. № 2. P. 66–78.
  26. Макнамара-Гуджер К. и Фойдтнер К. Глава 1. История и эпидемиология. С. 5. Паллиативная помощь детям. Под редакцией Э. Голдман, Р. Хейна и С. Либена. Пер с англ. – М.: Практика, 2017. – 672 с.
  27. Mattson R.H. et al. Comparison of Carbamazepine, Phenobarbital, Phenytoin, and Primidone in Partial and Secondarily Generalized Tonic–Clonic Seizures // N. Engl. J. Med. New England Journal of Medicine (NEJM/MMS), 1985. Vol. 313, № 3. P. 145–151.
  28. Nevitt S.J. et al. Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data // Cochrane Database Syst. Rev. Wiley, 2017. Vol. 12, № 12.
  29. Lattanzi S. et al. Antiepileptic monotherapy in newly diagnosed focal epilepsy. A network meta-analysis // Acta Neurologica Scandinavica. Blackwell Publishing Ltd, 2019. Vol. 139, № 1. P. 33–41.
  30. Campos M.S. de A. et al. Efficacy and Tolerability of Antiepileptic Drugs in Patients with Focal Epilepsy: Systematic Review and Network Meta-analyses // Pharmacotherapy. Pharmacotherapy Publications Inc., 2016. Vol. 36, № 12. P. 1255–1271.
  31. Baulac M. et al. Efficacy, safety, and tolerability of lacosamide monotherapy versus controlled- release carbamazepine in patients with newly diagnosed epilepsy: a phase 3, randomised, double- blind, non-inferiority trial // Lancet Neurol. Lancet Publishing Group, 2017. Vol. 16, № 1. P. 43-54.
  32. Marson A.G. et al. Carbamazepine versus valproate monotherapy for epilepsy // Cochrane Database Syst. Rev. Wiley, 2000. Vol. 2000, № 3.
  33. Nevitt S.J. et al. Topiramate versus carbamazepine monotherapy for epilepsy: An individual participant data review // Cochrane Database of Systematic Reviews. John Wiley and Sons Ltd, 2019. Vol. 2019, № 6.
  34. Nevitt S.J. et al. Lamotrigine versus carbamazepine monotherapy for epilepsy: An individual participant data review // Cochrane Database of Systematic Reviews. John Wiley and Sons Ltd, 2018. Vol. 2018, № 6.
  35. Brodie M.J. et al. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy // Neurology. Neurology, 2007. Vol. 68, № 6. P. 402–408.
  36. Trinka E. et al. KOMET: An unblinded, randomised, two parallelgroup, stratified trial comparing the effectiveness of levetiracetam with controlled-release carbamazepine and extended- release sodium valproate as monotherapy in patients with newly diagnosed epilepsy // J. Neurol. Neurosurg. Psychiatry. BMJ Publishing Group, 2013. Vol. 84, № 10. P. 1138–1147.
  37. Marson A. et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: An unblinded randomised controlled trial // Lancet. 2007. Vol. 369. P. 1016–1026.
  38. Glauser T. et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes // Epilepsia. Epilepsia, 2013. Vol. 54, № 3. P. 551–563.
  39. Brigo F. et al. Clonazepam monotherapy for treating people with newly diagnosed epilepsy // Cochrane Database of Systematic Reviews. John Wiley and Sons Ltd, 2019. Vol. 2019, № 11.
  40. Lattanzi S. et al. Antiepileptic drug monotherapy for epilepsy in the elderly: A systematic review and network meta-analysis // Epilepsia. Blackwell Publishing Inc., 2019. Vol. 60, № 11. P. 2245–2254.
  41. Rowan A.J. et al. New onset geriatric epilepsy: A randomized study of gabapentin, lamotrigine, and carbamazepine // Neurology. Lippincott Williams and Wilkins, 2005. Vol. 64, № 11. P. 1868–1873.
  42. Авакян Г.Н. et al. Ограничения использования вальпроевой кислоты у девочек и женщин: расширение противопоказаний в инструкции по медицинскому применению, основанное на данных реальной клинической практики // Эпилепсия и пароксизмальные состояния. Общество с ограниченной ответственностью «Ирбис», 2019. Vol. 11, № 2.
  43. Liu J., Wang L.N., Wang Y.P. Topiramatemonotherapyforjuvenilemyoclonicepilepsy // CochraneDatabaseofSystematicReviews. John Wiley and Sons Ltd, 2017. Vol. 2017, № 4.
  44. Wiebe S., Jette N. Pharmacoresistance and the role of surgery in difficult to treat epilepsy // Nat. Rev. Neurol. Nat Rev Neurol, 2012. Vol. 8, № 12. P. 669–677.
  45. Bodalia P.N. et al. Comparative efficacy and tolerability of anti-epileptic drugs for refractory focal epilepsy: Systematic review and network meta-analysis reveals the need for long term comparator trials // Br. J. Clin. Pharmacol. Br J Clin Pharmacol, 2013. Vol. 76, № 5. P. 649–667.
  46. Ma J., Huang S., You C. Adjunctive brivaracetam for patients with refractory partial seizures: A meta-analysis of randomized placebo-controlled trials // Epilepsy Res. Elsevier, 2015. Vol. 114. P. 59– 65.
  47. French J.A. et al. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: Results of randomized global phase III study 305 // Epilepsia. Epilepsia, 2013. Vol. 54, № 1. P. 117–125.
  48. Elger C. et al. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: A randomized, double-blind, placebo-controlled, parallel-group phase III study // Epilepsia. Epilepsia, 2009. Vol. 50, № 3. P. 454–463.
  49. Song L. et al. Clonazepam add-on therapy for drug-resistant epilepsy // Cochrane Database of Systematic Reviews. John Wiley and Sons Ltd, 2020. Vol. 2020, № 4.
  50. Colleran N., O Connor T., O Brien J.J. Anti epileptic drug trials for patients with drug resistant idiopathic generalised epilepsy: A meta-analysis // Seizure. W.B. Saunders Ltd, 2017. Vol. 51. P. 145– 156.
  51. Marson A. et al. The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non- inferiority, multicentre, phase 4, randomised controlled trial // Lancet. Elsevier B.V., 2021. Vol. 397, № 10282. P. 1375–1386.
  52. Воронкова К.В. и др. Современный выбор антиэпилептической терапии: этапы и рекомендации //Эпилепсия и пароксизмальные состояния. – 2018. – Т. 10. – №. 2.
  53. Booth D., Evans D.J. Anticonvulsants for neonates with seizures // Cochrane Database Syst. Rev. Wiley, 2004. № 4.
  54. Ijff D.M., Aldenkamp A.P. Cognitive side-effects of antiepileptic drugs in children // Handbook of Clinical Neurology. Elsevier B.V., 2013. Vol. 111. P. 707–718.
  55. Bensch J. et al. A Double‐blind Study of Clonazepam in the Treatment of Therapy‐resistant Epilepsy in Children // Dev. Med. Child Neurol. Dev Med Child Neurol, 1977. Vol. 19, № 3. P. 335– 342.
  56. Guerreiro M.M. et al. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy // Epilepsy Res. Epilepsy Res, 1997. Vol. 27, № 3. P. 205–213.
  57. Glauser TA et al. Adjunctive therapy with oxcarbazepine in children with partial seizures. The Oxcarbazepine Pediatric Study Group. Neurology. 2000; 54(12):2237–44.
  58. Bittencourt PR, Antoniuk SA, Bigarella MM, da Costa JC, Doro MP, Ferreira AS, et al. Carbamazepine and phenytoin in epilepsies refractory to barbiturates: efficacy, toxicity and mental function. Epilepsy Res. 1993;16(2):147–55
  59. Wheless J.W. et al. Treatment of pediatric epilepsy: European expert opinion, 2007 // Epileptic Disord. Epileptic Disord, 2007. Vol. 9, № 4. P. 353–412.
  60. Pina-Garza J.E.; Nordli D.R.; Rating D.; Yang H.; Schiemann-Delgado J.; Duncan B.; Adjunctive levetiracetam in infants and young children with refractory partial-onset seizures; Epilepsia;2009;50;5:1141-1149
  61. Glauser T.A. et al. Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures // Neurology. Neurology, 2006. Vol. 66, № 11. P. 1654–1660.
  62. Rosenfeld W.E. et al. Levetiracetam as add-on therapy for idiopathic generalized epilepsy syndromes with onset during adolescence: Analysis of two randomized, double-blind, placebo- controlled studies // Epilepsy Res. Epilepsy Res, 2009. Vol. 85, № 1. P. 72–80.
  63. Arzimanoglou A, Ferreira J, Satlin A, Olhaye O, Kumar D, Dhadda S, Bibbiani F. Evaluation of long-term safety, tolerability, and behavioral outcomes with adjunctive rufinamide in pediatric patients (≥1 to <4 years old) with Lennox-Gastaut syndrome: Final results from randomized study 303. Eur J Paediatr Neurol. 2019 Jan;23(1):126-135.
  64. Ohtsuka Y. et al. Rufinamide as an adjunctive therapy for Lennox-Gastaut syndrome: A randomized double-blind placebo-controlled trial in Japan // Epilepsy Res. Elsevier B.V., 2014. Vol. 108, № 9. P. 1627–1636.
  65. Gilliam FG, Veloso F, Bomhof MA, Gazda SK, Biton V, Ter Bruggen JP, Neto W, Bailey C, Pledger G, Wu SC. A dose-comparison trial of topiramate as monotherapy in recently diagnosed partial epilepsy. Neurology. 2003 Jan 28;60(2):196-202. doi: 10.1212/01.wnl.0000048200.12663.bc. PMID: 12552030.
  66. Sachdeo R.C. et al. A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome // Neurology. Lippincott Williams and Wilkins, 1999. Vol. 52, № 9. P. 1882–1887.
  67. Frank L.M. et al. Lamictal (lamotrigine) monotherapy for typical absence seizures in children // Epilepsia. Lippincott Williams and Wilkins, 1999. Vol. 40, № 7. P. 973–979.
  68. Smith D, Baker G, Davies G, Dewey M, Chadwick DW. Outcomes of add-on treatment with lamotrigine in partial epilepsy. Epilepsia. 1993 Mar-Apr;34(2):312-22. doi: 10.1111/j.1528- 1157.1993.tb02417.x. PMID: 8453943
  69. Duchowny M. et al. A placebo-controlled trial of lamotrigine add-on therapy for partial seizures in children // Neurology. Lippincott Williams and Wilkins, 1999. Vol. 53, № 8. P. 1724–1731.
  70. Trevathan E. et al. Lamotrigine adjunctive therapy among children and adolescents with primary generalized tonic-clonic seizures // Pediatrics. Pediatrics, 2006. Vol. 118, № 2.
  71. Motte J. et al. Lamotrigine for Generalized Seizures Associated with the Lennox–Gastaut Syndrome // N. Engl. J. Med. New England Journal of Medicine (NEJM/MMS), 1997. Vol. 337, № 25. P. 1807–1812.
  72. Белоусова Е.Д., Шулякова И.В., Охапкина Т.Г. Гормональная терапия синдрома Веста // Журнал неврологии и психиатрии им. C.C. Корсакова. Общество с ограниченной ответственностью Издательство Медиа Сфера, 2016. Vol. 116, № 9–2. P. 61–66.
  73. Guerrini R. Et al. A randomized phase III trial of adjunctive zonisamide in pediatric patients with partial epilepsy // Epilepsia. Epilepsia, 2013. Vol. 54, № 8. P. 1473–1480.
  74. Brigo F., Igwe S.C. Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents // Cochrane Database of Systematic Reviews. John Wiley and Sons Ltd, 2017. Vol. 2017, № 2.
  75. Wallace S.J. Myoclonus and epilepsy in childhood: A review of treatment with valproate, ethosuximide, lamotrigine and zonisamide // Epilepsy Res. Epilepsy Res, 1998. Vol. 29, № 2. P. 147– 154.
  76. Krauss G.L. et al. Randomized phase III study 306 Adjunctive perampanel for refractory partial-onset seizures // Neurology. Lippincott Williams and Wilkins, 2012. Vol. 78, № 18. P. 1408– 1415.
  77. French J.A. et al. Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy. A randomized trial // Neurology. Lippincott Williams and Wilkins, 2015. Vol. 85, № 11. P. 950–957.
  78. Fogarasi A. et al. Open-label study to investigate the safety and efficacy of adjunctive perampanel in pediatric patients (4 to <12 years) with inadequately controlled focal seizures or generalized tonic-clonic seizures // Epilepsia. Blackwell Publishing Inc., 2020. Vol. 61, № 1. P. 125– 137.
  79. Farkas V. et al. Efficacy and tolerability of adjunctive lacosamide in pediatric patients with focal seizures // Neurology. Neurology, 2019. Vol. 93, № 12. P. E1212–E1226.
  80. Chadwick D.W. et al. A double-blind trial of gabapentin monotherapy for newly diagnosed partial seizures // Neurology. Lippincott Williams and Wilkins, 1998. Vol. 51, № 5. P. 1282–1288.
  81. Panebianco M. et al. Gabapentin add-on treatment for drug-resistant focal epilepsy // Cochrane Database of Systematic Reviews. John Wiley and Sons Ltd, 2018. Vol. 2018, № 10.
  82. Klein P. et al. A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures // Epilepsia. Blackwell Publishing Inc., 2015. Vol. 56, № 12. P. 1890–1898.
  83. Bresnahan R. et al. Clobazam add-on therapy for drug-resistant epilepsy // Cochrane Database of Systematic Reviews. John Wiley and Sons Ltd, 2019. Vol. 2019, № 10.
  84. Ng Y.T. et al. Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome // Neurology. Lippincott Williams and Wilkins, 2011. Vol. 77, № 15. P. 1473–1481.
  85. Sofou K, Kristjánsdóttir R, Papachatzakis NE, Ahmadzadeh A, Uvebrant P.J Management of prolonged seizures and status epilepticus in childhood: a systematic review. Child Neurol. 2009 Aug;24(8):918-26. doi: 10.1177/0883073809332768. Epub 2009 Mar 30
  86. Wolf P. Acute Drug Administration in Epilepsy: A Review // CNS Neurosci. Ther. CNS Neurosci Ther, 2011. Vol. 17, № 5. P. 442–448.
  87. Brigo F. et al. Nonintravenous midazolam versus intravenous or rectal diazepam for the treatment of early status epilepticus: A systematic review with meta-analysis // Epilepsy Behav. Epilepsy Behav, 2015. Vol. 49. P. 325–336.
  88. Pavlidou E., Tzitiridou M., Panteliadis C. Effectiveness of intermittent diazepam prophylaxis in febrile seizures: Long-term prospective controlled study // J. Child Neurol. J Child Neurol, 2006. Vol. 21, № 12. P. 1036–1040.
  89. McIntyre J. et al. Safety and efficacy of buccal midazolam versus rectal diazepam for emergency treatment of seizures in children: A randomised controlled trial // Lancet. Elsevier B.V., 2005. Vol. 366, № 9481. P. 205–21.
  90. Li S. et al. Prednisolone/prednisone as adrenocorticotropic hormone alternative for infantile spasms: a meta-analysis of randomized controlled trials // Developmental Medicine and Child Neurology. Blackwell Publishing Ltd, 2020. Vol. 62, № 5. P. 575–580.
  91. Rajpurohit M. et al. Safety, Feasibility and Effectiveness of Pulse Methylprednisolone Therapy in Comparison with Intramuscular Adrenocorticotropic Hormone in Children with West Syndrome // Indian J. Pediatr. Springer, 2020.
  92. Haberlandt E. et al. Adrenocorticotropic Hormone versus Pulsatile Dexamethasone in the Treatment of Infantile Epilepsy Syndromes // Pediatr. Neurol. Pediatr Neurol, 2010. Vol. 42, № 1. P. 21–27.
  93. Прыгунова Т.М. Синдром Веста: отдаленные исходы в зависимости от этиологии и лечения (обзор литературы) // Русский журнал детской неврологии. Общество с ограниченной ответственностью «Издательский дом «АБВ-пресс», 2018. Vol. 13, № 4.
  94. Coughlin CR 2nd, Tseng LA, Abdenur JE, Ashmore C, Boemer F, Bok LA, Boyer M, Buhas D, Clayton PT, Das A, Dekker H, Evangeliou A, Feillet F, Footitt EJ, Gospe SM Jr, Hartmann H, Kara M, Kristensen E, Lee J, Lilje R, Longo N, Lunsing RJ, Mills P, Papadopoulou MT, Pearl PL, Piazzon F, Plecko B, Saini AG, Santra S, Sjarif DR, Stockler-Ipsiroglu S, Striano P, Van Hove JLK, Verhoeven- Duif NM, Wijburg FA, Zuberi SM, van Karnebeek CDM. Consensus guidelines for the diagnosis and management of pyridoxine-dependent epilepsy due to α-aminoadipic semialdehyde dehydrogenase deficiency. J Inherit Metab Dis. 2021 Jan;44(1):178-192. doi: 10.1002/jimd.12332. Epub 2020 Dec 1. PMID: 33200442.
  95. Шалькевич Л.В., Шанько Г.Г., Кот Д.А. Кортикостероидная терапия фармакорезистентных эпилепсий у детей // Международный неврологический журнал. ФЛП «ЗаславскийАлександрЮрьевич», 2014. № 3 (65). P. 20–27.
  96. deVries E.E. et al. Inflammatory mediators in human epilepsy: A systematic review and meta- analysis // Neuroscience and Biobehavioral Reviews. ElsevierLtd, 2016. Vol. 63. P. 177–190.
  97. Белоусова Е.Д., Ермаков A.Ю. Эпилептическая энцефалопатия с продолженной спайк- волновой активностью во сне: обзор литературы // Журнал неврологии и психиатрии им. ССКорсакова. Спецвыпуски. Издательство ’МедиаСфера’, 2014. Vol. 114, № 4. P. 52–58.
  98. IizukaT, KanazawaN, KanekoJ, TominagaN, NonodaY, HaraA, OnozawaY, AsariH, HataT, KanekoJ, YoshidaK, SugiuraY, UgawaY, WatanabeM, TomitaH, KosakaiA, KanekoA, IshimaD, KitamuraE, NishiyamaK. CryptogenicNORSE: Itsdistinctiveclinicalfeaturesandresponsetoimmunotherapy. Neurol Neuroimmunol Neuroinflamm. 2017 Sep 25;4(6):e396. doi: 10.1212/NXI.0000000000000396. PMID: 28959704; PMCID: PMC5614728.
  99. Белоусова Е.Д., Яблонская М.И., Тагирова М.К. и соавт. Иммунообусловленные эпилепсии у детей // Российский вестник перинатологии и педиатрии, 2015. Vol. 60, № 5. P. 26– 32.
  100. NabboutR. еt al. Efficacy of ketogenic diet in severe refractory status epilepticus initiating fever induced refractory epileptic encephalopathy in school age children (FIRES) // Epilepsia. Epilepsia, 2010. Vol. 51, № 10. P. 2033–2037.
  101. Bello-Espinosa LE, Rajapakse T, Rho JM, Buchhalter J. Efficacy of intravenous immunoglobulin in a cohort of children with drug-resistant epilepsy. Pediatr Neurol. 2015 May;52(5):509-16. doi: 10.1016/j.pediatrneurol.2014.11.011. Epub 2015 Feb 13. PMID: 25882078.
  102. Rezaei S. et al. Short-term and long-term efficacy of classical ketogenic diet and modified Atkins diet in children and adolescents with epilepsy: A systematic review and meta-analysis // Nutritional Neuroscience. Taylor and Francis Ltd., 2019. Vol. 22, № 5. P. 317–334.
  103. Englot D.J., Chang E.F., Auguste K.I. Vagus nerve stimulation for epilepsy: A meta-analysis of efficacy and predictors of response - A review // Journal of Neurosurgery. J Neurosurg, 2011. Vol. 115, № 6. P. 1248–1255.
  104. Maragkos G.A. et al. Quality of Life after Epilepsy Surgery in Children: A Systematic Review and Meta-Analysis // Clinical Neurosurgery. Oxford University Press, 2019. Vol. 85, № 6. P. 741–749.
  105. Tomson T. et al. Executive Summary: Management of epilepsy in pregnancy: A report from the International League Against Epilepsy Task Force on Women and Pregnancy // Epilepsia. Blackwell Publishing Inc., 2019. Vol. 60, № 12. P. 2343–2345.
  106. Thomas S. V., Syam U., Devi J.S. Predictors of seizures during pregnancy in women with epilepsy // Epilepsia. 2012. Vol. 53, № 5.
  107. Vajda F.J.E. et al. Seizure control in antiepileptic drug-treated pregnancy // Epilepsia. Blackwell Publishing Inc., 2008. Vol. 49, № 1. P. 172–176.
  108. Battino D. et al. Seizure control and treatment changes in pregnancy: Observations from the EURAP epilepsy pregnancy registry // Epilepsia. Epilepsia, 2013. Vol. 54, № 9. P. 1621–1627.
  109. Hiilesmaa V.K., Teramo K.A. Fetal and Maternal Risks with Seizures // Epilepsy in Women. John Wiley and Sons, 2013. P. 115–127.
  110. Edey S., Moran N., Nashef L. SUDEP and epilepsy-related mortality in pregnancy // Epilepsia. Blackwell Publishing Inc., 2014. Vol. 55, № 7.
  111. EURAP - International Registry of Antiepileptic Drugs and Pregnancy [Electronic resource]. URL: https://eurapinternational.org/ (accessed: 30.05.2021).
  112. Tomson T., Battino D., Perucca E. Teratogenicity of antiepileptic drugs // Curr. Opin. Neurol. Lippincott Williams and Wilkins, 2019. Vol. 32, № 2. P. 246–252.
  113. Blotière P.O. et al. Risks of 23 specific malformations associated with prenatal exposure to 10 antiepileptic drugs // Neurology. Lippincott Williams and Wilkins, 2019. Vol. 93, № 2. P. E167–E180.
  114. Карлов В.А. et al. Эпилепсия и беременность // Эпилепсия у детей и взрослых женщин и мужчин. Второе издание / ed. Карлов В.А. Москва: Издательство БИНОМ, 2019. P. 672–690.
  115. Карлов В.А., Бурд С.Г., Михаловска-Карлова Е.П. Современность и эпилепсия. Современные и биоэтические аспекты эпилепсии. // Эпилепсия у детей и взрослых женщин и мужчин». Руководство для врачей. Второе издание. / ed. Карлов В.А. Москва: Издательство БИНОМ, 2019. P. 868–891.
  116. Власов П.Н. Применение противоэпилептических препаратов во время беременности // Фармакотерапия отдельных состояний при беременности / ed. Володин Н.Н., Белоусов Ю.Б., Зырянов С.К. Москва: Миклош, 2012. P. 127–137.
  117. Pariente G. Et al. Pregnancy Outcomes Following In Utero Exposure to Lamotrigine: A Systematic Review and Meta-Analysis // CNS Drugs. Adis, 2017. Vol. 31, № 6. P. 439–450.
  118. Veroniki A.A. et al. Comparative safety of anti-epileptic drugs during pregnancy: A systematic review and network meta-analysis of congenital malformations and prenatal outcomes // BMC Med. BioMed Central Ltd., 2017. Vol. 15, № 1.
  119. Morrow J.I. et al. Folic acid use and major congenital malformations in offspring of women with epilepsy: A prospective study from the UK Epilepsy and pregnancy register // J. Neurol. Neurosurg. Psychiatry. J Neurol Neurosurg Psychiatry, 2009. Vol. 80, № 5. P. 506–511.
  120. Tomson T. et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry // Lancet Neurol. Lancet Publishing Group, 2018. Vol. 17, № 6. P. 530–538.
  121. Meador K.J. et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): A prospective observational study // Lancet Neurol. Lancet Neurol, 2013. Vol. 12, № 3. P. 244–252
  122. Minicucci F., Ferlisi M., Brigo F., Mecarelli O., Meletti S., Aguglia U., Michelucci R., Mastrangelo M., Specchio N., Sartori S., Tinuper P. Management of status epilepticus in adults. Position paper of the Italian League against Epilepsy. Epilepsy & Behavior 102 (2020)
  123. Kilbride R.D., Reynolds A.S., Szaflarski J.P., Hirsch L.J. Clinical outcomes following prolonged refractory status epilepticus (PRSE). Neurocrit Care 2013; 18 (3):374-385.
  124. Özkara Ç. et al. Surgical outcome of epilepsy patients evaluated with a noninvasive protocol // Epilepsia. Lippincott Williams and Wilkins, 2000. Vol. 41, № SUPPL. 4.
  125. Jette N., Reid A.Y., Wiebe S. Surgical management of epilepsy // CMAJ. Canadian Medical Association, 2014. Vol. 186, № 13. P. 997–1004.
  126. Wiebe S., Jette N. Pharmacoresistance and the role of surgery in difficult to treat epilepsy // Nat. Rev. Neurol. Nat Rev Neurol, 2012. Vol. 8, № 12. P. 669–677.
  127. Spencer S., Huh L. Outcomes of epilepsy surgery in adults and children // Lancet Neurol. Lancet Neurol, 2008. Vol. 7, № 6. P. 525–537.
  128. Spencer S.S. et al. Health-related quality of life over time since resective epilepsy surgery // Ann. Neurol. Ann Neurol, 2007. Vol. 62, № 4. P. 327–334.
  129. Ryvlin P., Cross J.H., Rheims S. Epilepsy surgery in children and adults // Lancet Neurol. Lancet Publishing Group, 2014. Vol. 13, № 11. P. 1114–1126.
  130. Velasco A.L. et al. Electrical stimulation of the hippocampal epileptic foci for seizure control: A double-blind, long-term follow-up study // Epilepsia. Epilepsia, 2007. Vol. 48, № 10. P. 1895–1903.
  131. Neligan A. et al. A survey of adult and pediatric epilepsy surgery in the United Kingdom // Epilepsia. Epilepsia, 2013. Vol. 54, № 5.
  132. Niemeyer P. The transventricular amygdalohippocampectomy in temporal lobe epilepsy // Temporal lobe epilepsy. Charles C Thomas, 1958. P. 461–482.
  133. Vakharia V.N. et al. Getting the best outcomes from epilepsy surgery // Ann. Neurol. John Wiley and Sons Inc., 2018. Vol. 83, № 4. P. 676–690.
  134. Crandall P.H. Standard en bloc anterior temporal lobectomy // Surgery for epilepsy. Blackwell Scientific Publications, Boston, 1991. P. 118–129.
  135. Wyler A.R. Anterior temporal lobectomy // Surg. Neurol. Surg Neurol, 2000. Vol. 54, № 5. P. 341–345.
  136. Wen H.T. et al. Microsurgical anatomy of the temporal lobe: Part 1: Mesial temporal lobe anatomy and its vascular relationships as applied to amygdalohippocampectomy // Neurosurgery. Lippincott Williams and Wilkins, 1999. Vol. 45, № 3. P. 549–592.
  137. Spencer D.D. et al. Access to the posterior medial temporal lobe structures in the surgical treatment of temporal lobe epilepsy // Neurosurgery. Neurosurgery, 1984. Vol. 15, № 5. P. 667–671.
  138. Noachtar S., Borggraefe I. Epilepsy surgery: A critical review // Epilepsy Behav. Epilepsy Behav, 2009. Vol. 15, № 1. P. 66–72.
  139. Connor D.E. et al. Vagal nerve stimulation for the treatment of medically refractory epilepsy: A review of the current literature // Neurosurg. Focus. Neurosurg Focus, 2012. Vol. 32, № 3.
  140. Morris G.L. et al. Evidence-based guideline update: Vagus nerve stimulation for the treatment of epilepsy: Report of the guideline development subcommittee of the american academy of neurology // Neurology. Neurology, 2013. Vol. 81, № 16. P. 1453–1459.
  141. Manuals « VNS Therapy « Healthcare Professionals, on VNS Therapy for Epilepsy | Cyberonics US [Electronic resource]. URL: https://dynamic.cyberonics.com/manuals/index_iframe_test.asp?lang=English-US (accessed: 30.05.2021).
  142. Josephson C.B. et al. Systematic review and meta-analysis of standard vs selective temporal lobe epilepsy surgery // Neurology. Neurology, 2013. Vol. 80, № 18. P. 1669–1676.
  143. Morrell F., Whisler W.W., Bleck T.P. Multiple subpial transection: A new approach to the surgical treatment of focal epilepsy // J. Neurosurg. J Neurosurg, 1989. Vol. 70, № 2. P. 231–239.
  144. Spencer S.S. et al. Multiple subpial transection for intractable partial epilepsy: An international meta-analysis // Epilepsia. Epilepsia, 2002. Vol. 43, № 2. P. 141–145.
  145. Hufnagel A. et al. Multiple subpial transection for control of epileptic seizures: Effectiveness and safety // Epilepsia. Epilepsia, 1997. Vol. 38, № 6. P. 678–688.
  146. Gates J.R. et al. Response of Multiple Seizure Types to Corpus Callosum Section // Epilepsia. Epilepsia, 1987. Vol. 28, № 1. P. 28–34.
  147. Wilson D.H., Reeves A.G., Gazzaniga M.S. “Central” commissurotomy for intractable generalized epilepsy: Series two // Neurology. Neurology, 1982. Vol. 32, № 7. P. 687–697.
  148. Wyllie E. Catastrophic epilepsy in infants and children: Identification of surgical candidates // Epileptic Disord. Epileptic Disord, 1999. Vol. 1, № 4. P. 261–264.
  149. Carreño M. et al. Intractable epilepsy in vascular congenital hemiparesis: Clinical features and surgical options // Neurology. Lippincott Williams and Wilkins, 2002. Vol. 59, № 1. P. 129–131.
  150. González-Martínez J.A. et al. Hemispherectomy for catastrophic epilepsy in infants // Epilepsia. Epilepsia, 2005. Vol. 46, № 9. P. 1518–1525.
  151. Elsharkawy A.E. et al. Outcome of extratemporal epilepsy surgery experience of a single center // Neurosurgery. Neurosurgery, 2008. Vol. 63, № 3. P. 516–525.
  152. Крылов В.В.Хирургия эпилепсии. АБВ-пресс, 2019.
  153. Bauer S., Hamer H.M. Extratemporal epilepsies // Handbook of Clinical Neurology. Elsevier B.V., 2012. Vol. 107. P. 241–256.
  154. Greiner H.M. et al. Preresection intraoperative electrocorticography (ECoG) abnormalities predict seizure-onset zone and outcome in pediatric epilepsy surgery // Epilepsia. Blackwell Publishing Inc., 2016. Vol. 57, № 4. P. 582–589.
  155. Kaufmann E. et al. European Expert Opinion on ANT-DBS therapy for patients with drug- resistant epilepsy (a Delphi consensus) // Seizure. W.B. Saunders Ltd, 2020. Vol. 81. P. 201–209.
  156. Salanova V. et al. Long-term efficacy and safety of thalamic stimulation for drug-resistant partial epilepsy // Neurology. Lippincott Williams and Wilkins, 2015. Vol. 84, № 10. P. 1017–1025.
  157. Parent M., Parent A. Single-axon tracing and three-dimensional reconstruction of centre médian-parafascicular thalamic neurons in primates // J. Comp. Neurol. J Comp Neurol, 2005. Vol. 481, № 1. P. 127–144.
  158. Handforth A., DeSalles A.A.F., Krahl S.E. Deep brain stimulation of the subthalamic nucleus as adjunct treatment for refractory epilepsy // Epilepsia. Epilepsia, 2006. Vol. 47, № 7. P. 1239–1241.
  159. Wellmer J., Voges J., Parpaley Y. Lesion guided radiofrequency thermocoagulation (L-RFTC) for hypothalamic hamartomas, nodular heterotopias and cortical dysplasias: Review and perspective // Seizure. W.B. aunders Ltd, 2016. Vol. 41. P. 206–210.
  160. Kameyama S. et al. MRI-guided stereotactic radiofrequency thermocoagulation for 100 hypothalamic hamartomas // J. Neurosurg. American Association of Neurological Surgeons, 2016. Vol. 124, № 5. P. 1503–1512.
  161. Catenoix H. et al. SEEG-guided thermocoagulations: A palliative treatment of nonoperable partial epilepsies // Neurology. Lippincott Williams and Wilkins, 2008. Vol. 71, № 21. P. 1719–1726.
  162. Gopinath S. et al. Seizure outcome following primary motor cortex-sparing resective surgery for perirolandic focal cortical dysplasia // Int. J. Surg. Elsevier Ltd, 2016. Vol. 36, № Pt B. P. 466–476.
  163. Mula M., Sander J.W. Current and emerging drug therapies for the treatment of depression in adults with epilepsy // Expert Opinion on Pharmacotherapy. Taylor and Francis Ltd, 2019. Vol. 20, № 1. P. 41–45.
  164. Orjuela-Rojas J.M. et al. Treatment of depression in patients with temporal lobe epilepsy: A pilot study of cognitive behavioral therapy vs. selective serotonin reuptake inhibitors // Epilepsy Behav. Academic Press Inc., 2015. Vol. 51. P. 176–181.
  165. Li W., Ma D. A randomized controlled trial to evaluate the efficacy of paroxetine and doxepin in treating epileptic patients with depression // Zhong Linch Kangfu. 2005. Vol. 9. P. 20–21.
  166. Усюкина М.В. Систематика и принципы терапии депрессивных расстройств при эпилепсии// Нервно-мышечные болезни. 2015. № 4. URL: https://cyberleninka.ru/article/n/sistematika-i-printsipy-terapii-depressivnyh-rasstroystv-pri-epilepsii (дата обращения: 16.07.2021).
  167. Hovorka J., Herman E., Nemcová I. Treatment of interictal depression with citalopram in patients with epilepsy // Epilepsy Behav. Epilepsy Behav, 2000. Vol. 1, № 6. P. 444–447.
  168. Specchio L.M. et al. Citalopram as treatment of depression in patients with epilepsy // Clin. Neuropharmacol. Clin Neuropharmacol, 2004. Vol. 27, № 3. P. 133–136.
  169. Kühn K.U. et al. Antidepressive treatment in patients with temporal lobe epilepsy and major depression: A prospective study with three different antidepressants // Epilepsy Behav. Academic Press Inc., 2003. Vol. 4, № 6. P. 674–679.
  170. Gilliam F.G. et al. A Trial of Sertraline or Cognitive Behavior Therapy for Depression in Epilepsy // Ann. Neurol. John Wiley and Sons Inc., 2019. Vol. 86, № 4. P. 552–560.
  171. Kanner A.M., Kozak A.M., Frey M. The use of sertraline in patients with epilepsy: Is it safe? // Epilepsy Behav. Epilepsy Behav, 2000. Vol. 1, № 2. P. 100–105.
  172. Zhu S.Q., Luo L.J., YaX G. Short-Term efficacy of venlafaxine treating the depression in epilepsy patients // Chin J Rehabil. 2004. Vol. 19. P. 101.
  173. Носов С.Г. Депрессия и эпилепсия: общие патогенетические закономерности развития и особенности лечения (обзор литературы) //Український вісник психоневрології. – 2012. – Т. 20. – №. 4. – С. 92-
  174. Robertson M.M., Trimble M.R. The treatment of depression in patients with epilepsy A double- blind trial // J. Affect. Disord. J Affect Disord, 1985. Vol. 9, № 2. P. 127–136.
  175. Alper K. et al. Seizure Incidence in Psychopharmacological Clinical Trials: An Analysis of Food and Drug Administration (FDA) Summary Basis of Approval Reports // Biol. Psychiatry. Biol Psychiatry, 2007. Vol. 62, № 4. P. 345–354.
  176. Italiano D., Spina E., De Leon J. Pharmacokinetic and pharmacodynamic interactions between antiepileptics and antidepressants // Expert Opin. Drug Metab. Toxicol. Informa Healthcare, 2014. Vol. 10, № 11. P. 1457–1489.
  177. Unterecker S. et al. Interaction of valproic acid and the antidepressant drugs doxepin and venlafaxine: Analysis of therapeutic drug monitoring data under naturalistic conditions // Int. Clin. Psychopharmacol. Lippincott Williams and Wilkins, 2014. Vol. 29, № 4. P. 206–211.
  178. Hemeryck A., Belpaire F. Selective Serotonin Reuptake Inhibitors and Cytochrome P-450 Mediated Drug-Drug Interactions: An Update // Curr. Drug Metab. Bentham Science Publishers Ltd., 2002. Vol. 3, № 1. P. 13–37.
  179. Berigan T., Harazin J. A sertraline/valproic acid drug interaction // Int. J. Psychiatry Clin. Pract. Martin Dunitz Ltd, 1999. Vol. 3, № 4. P. 287–288.
  180. Macrodimitris S. et al. Group cognitive-behavioral therapy for patients with epilepsy and comorbid depression and anxiety // Epilepsy Behav. Epilepsy Behav, 2011. Vol. 11, № 1. P. 83–88.
  181. Gandy M. et al. A feasibility trial of an Internet-delivered and transdiagnostic cognitive behavioral therapy treatment program for anxiety, depression, and disability among adults with epilepsy // Epilepsia. Blackwell Publishing Inc., 2016. Vol. 57, № 11. P. 1887–1896.
  182. Пешеходько Д. И. Депрессия и тревожность при детской эпилепсии: обзорный анализ / Д.И. Пешеходько, Б.Д. Абдулазизов, А.А. Некишева // Перспективы науки. – 2020. – № 12(135). – С. 206-208.
  183. Mula M. Pharmacological treatment of anxiety disorders in adults with epilepsy // Expert Opin. Pharmacother. Taylor and Francis Ltd, 2018. Vol. 19, № 17. P. 1867–1874.
  184. Mula M. Treatment of anxiety disorders in epilepsy: An evidence-based approach // Epilepsia. Epilepsia, 2013. Vol. 54, № SUPPL. 1. P. 13–18.
  185. Sepúlveda C. et al. Palliative care: The world health organization’s global perspective // J. Pain Symptom Manage. Elsevier Inc., 2002. Vol. 24, № 2. P. 91–96.
  186. Pastrana T. et al. A matter of definition - Key elements identified in a discourse analysis of definitions of palliative care // Palliat. Med. Palliat Med, 2008. Vol. 22, № 3. P. 222–232.
  187. Glauser T. et al. Evidence-based guideline: Treatment of convulsive status epilepticus in children and adults: Report of the guideline committee of the American epilepsy society // Epilepsy Currents. American Epilepsy Society, 2016. Vol. 16, № 1. P. 48–61.
  188. Kossoff EH, Zupec-Kania BA, Auvin S, et al. Optimal clinical management of children receiving dietary therapies for epilepsy: Updated recommendations of the International Ketogenic Diet Study Group. Epilepsia Open. 2018;3(2):175-192. Published 2018 May 21. doi:10.1002/epi4.12225
  189. D"Andrea Meira I, Romão TT, Pires do Prado HJ, Krüger LT, Pires MEP, da Conceição PO. Ketogenic Diet and Epilepsy: What We Know So Far. Front Neurosci. 2019;13:5. Published 2019 Jan 29. doi:10.3389/fnins.2019.00005
  190. Vancampfort D., Ward P.B., Stubbs B. Physical fitness levels and moderators in people with epilepsy: A systematic review and meta-analysis // Epilepsy Behav. Academic Press Inc., 2019. Vol. 99.
  191. Vancampfort D., Ward P.B., Stubbs B. Physical activity and sedentary levels among people living with epilepsy: A systematic review and meta-analysis // Epilepsy Behav. Academic Press Inc., 2019. Vol. 99.
  192. Deng B.W. et al. A Meta-analysis of the Effectiveness of Acupuncture in the Treatment of Epilepsy // Zhen ci yan jiu = Acupunct. Res. NLM (Medline), 2018. Vol. 43, № 4. P. 263–268.
  193. Nakken K.O., Brodtkorb E., Koht J. Epilepsi og rehabilitering // Tidsskr. Den Nor. legeforening. 2007.
  194. Helde G. et al. An easily performed group education programme for patients with uncontrolled epilepsy - A pilot study // Seizure. W.B. Saunders Ltd, 2003. Vol. 12, № 7. P. 497–501.
  195. Helde G. et al. A structured, nurse-led intervention program improves quality of life in patients with epilepsy: A randomized, controlled trial // Epilepsy Behav. Epilepsy Behav, 2005. Vol. 7, № 3. P. 451–457.
  196. Michaelis R. et al. Psychological treatments for people with epilepsy // Cochrane Database Syst. Rev. John Wiley and Sons Ltd, 2017. Vol. 2017, № 10.
  197. Haut S.R., Gursky J.M., Privitera M. Behavioral interventions in epilepsy // Curr. Opin. Neurol. Lippincott Williams and Wilkins, 2019. Vol. 32, № 2. P. 227–236.
  198. Schröder J. et al. Efficacy of a psychological online intervention for depression in people with epilepsy: A randomized controlled trial // Epilepsia. Epilepsia, 2014. Vol. 55, № 12. P. 2069–2076.
  199. Meyer B. et al. Effects of an epilepsy-specific Internet intervention (Emyna) on depression: Results of the ENCODE randomized controlled trial // Epilepsia. Epilepsia, 2019. Vol. 60, № 4. P. 656–668.
  200. Tang V., Michaelis R., Kwan P. Psychobehavioral therapy for epilepsy // Epilepsy Behav. Epilepsy Behav, 2014. Vol. 32. P. 147–155.
  201. Caller T.A. et al. A cognitive behavioral intervention (HOBSCOTCH) improves quality of life and attention in epilepsy // Epilepsy Behav. Epilepsy Behav, 2016. Vol. 57, № Pt A. P. 111–117.
  202. Казенных Т.В., Бохан Н.А. Роль психотерапевтической коррекции при проведении комплексной терапии у больных пароксизмальными состояниями различного генеза // Международный журнал прикладных и фундаментальных исследований. Общество с ограниченной ответственностью" Издательский Дом" Академия …, 2016. № 6–3. P. 470–476.
  203. Kertesz-BriestH.A. etal. Examining relations between neuropsychological and clinical epilepsy-specific factors with psychopathology and adaptive skills outcomes in youth with intractable epilepsy // Epilepsy Behav. EpilepsyBehav, 2020. Vol. 110.
  204. Приказ Министерства здравоохранения Российской Федерации от 28 сентября 2020 г. N 1029н «Об утверждении перечней медицинских показаний и противопоказаний для санаторно- курортного лечения» http://publication.pravo.gov.ru/Document/View/0001202010270044.
  205. WHO, ILAE, IBE. Epilepsy. A public health imperative. Geneva, 2019. xiii–xiii p.
  206. The Lancet. Epilepsy prevention: an urgent global unmet need // Lancet. Lancet Publishing Group, 2019. Vol. 393, № 10191. P. 2564.
  207. Приказ Министерства здравоохранения Российской Федерации от 24 декабря 2012 г. № 1404н “Об утверждении стандарта первичной медико-санитарной помощи при парциальной эпилепсии (фаза диагностики и подбора терапии)” [Electronicresource]. URL: https://minzdrav.gov.ru/documents/8345-prikaz-ministerstva-zdravoohraneniya-rossiyskoy-federatsii- ot-24-dekabrya-2012-g-1404n-ob-utverzhdenii-standarta-pervichnoy-mediko-sanitarnoy-pomoschi- pri-partsialnoy-epilepsii-faza-diagnostiki-i-podbora-terapii (accessed: 30.05.2021).
  208. Приказ Министерства здравоохранения Российской Федерации от 24 декабря 2012 г. № 1439н “Об утверждении стандарта первичной медико-санитарной помощи при генерализованной эпилепсии” [Electronicresource]. URL: https://minzdrav.gov.ru/documents/8348- prikaz-ministerstva-zdravoohraneniya-rossiyskoy-federatsii-ot-24-dekabrya-2012-g-1439n-ob- utverzhdenii-standarta-pervichnoy-mediko-sanitarnoy-pomoschi-pri-generalizovannoy-epilepsii (accessed: 30.05.2021).
  209. Приказ Министерства здравоохранения Российской Федерации от 24 декабря 2012 г.№ 1541н “Об утверждении стандарта специализированной медицинской помощи при эпилепсии” [Electronicresource]. URL: https://minzdrav.gov.ru/documents/8941-prikaz-ministerstva- zdravoohraneniya-rossiyskoy-federatsii-ot-24-dekabrya-2012-g-1541n-ob-utverzhdenii-standarta- spetsializirovannoy-meditsinskoy-pomoschi-pri-epilepsii.
  210. Приказ Министерства здравоохранения Российской Федерации от 05.07.2016 № 468н “Об утверждении стандарта скорой медицинской помощи при судорогах, эпилепсии, эпилептическом статусе” [Electronicresource]. URL: http://publication.pravo.gov.ru/Document/View/0001201607180038.
  211. Приказ Минздрава России от 10.12.2013 № 916н «О перечне видов высокотехнологичной медицинской помощи» [Electronicresource]. URL: https://minjust.consultant.ru/documents/8516.
  212. Labiner D.M. et al. Essential services, personnel, and facilities in specialized epilepsy centers- Revised 2010 guidelines // Epilepsia. Epilepsia, 2010. Vol. 51, № 11. P. 2322–2333.
  213. Benbadis S.R., Differential diagnosis of epilepsy: acritical review. Epilepsy Behav 15: 2009: 15– 21
  214. Wiglusz M.S., Landowski J, Michalak L, Cubała WJ. Validation of the Hospital Anxiety and Depression Scale in patients with epilepsy. Epilepsy Behav. 2016 May;58:97-101. doi: 10.1016/j.yebeh.2016.03.003. Epub 2016 Apr 9. PMID: 27064829.
  215. Котов А.С. Сбор анамнеза и осмотр у пациентов с эпилепсией. Клиническая лекция / А.С. Котов, К.В. Фирсов // Русский медицинский журнал. Медицинское обозрение. – 2019. – Т. 3. – № 7. – С. 4-7.
  216. Наумова Г. И. Организация медицинской помощи пациентам с впервые развившимся судорожным припадком // Неврология, нейропсихиатрия, психосоматика. 2009 (2): С. 37-41.
  217. Yeshokumar AK, Coughlin A, Fastman J, Psaila K, Harmon M, Randell T, Schorr EM, Han H, Hoang H, Soudant C, Jette N. Seizures in autoimmune encephalitis-A systematic review and quantitative synthesis. Epilepsia. 2021 Feb;62(2):397-407.
  218. Кочеткова О. Н. Нейроцистицеркоз: особенности клинико-патоморфологической картины, судорожного синдрома, современные методы диагностики и лечения / О.Н. Кочеткова, А.И. Кочетков // Вестник Воронежского государственного университета. Серия: Химия. Биология. Фармация. – 2013. – № 2. – С. 110-115.
  219. Еремин, А.О. Клинические особенности эпилепсии у пациентов с ВИЧ-инфекцией / А.О. Еремин, И.Н. Тихомирова // Вестник Совета молодых ученых и специалистов Челябинской области. – 2016. – Т. 5. – № 4(15). – С. 27-29.
  220. Фомина М.Ю., Щербук Ю.А., Воронин Е.Е., Рахманова А.Г. Особенности поражения нервной системы при перинатальной и парентеральной ВИЧ-инфекции / // Медико- биологические и социально-психологические проблемы безопасности в чрезвычайных ситуациях. – 2009. – № 2. – С. 55-61.
  221. Krumholz A. et al. Evidence-based guideline: Management of an unprovoked first seizure in adults // Neurology. Lippincott Williams and Wilkins, 2015. Vol. 84, № 16. P. 1705–1713.
  222. Koutroumanidis M. et al. The role of EEG in the diagnosis and classification of the epilepsy syndromes: a tool for clinical practice by the ILAE Neurophysiology Task Force (Part 2). EpilepticDisord. 2017 Dec 1;19(4):385-437. doi: 10.1684/epd.2017.0952. PMID: 29350182.
  223. Перепелова Е.М, Перепелов В.А, Меркулова М.С, Синицын В.Е. Современные подходы к диагностике с помощью магнитно-резонансной томографии эпилептогенных и сопряженных с ними поражений головного мозга. Неврология, нейропсихиатрия, психосоматика. 2018; (спецвыпуск 1):4-11.
  224. Wolf NI, Bast T, Surtees R. Epilepsy in inborn errors of metabolism. EpilepticDisord. 2005 Jun;7(2):67-81.
  225. Tomson T, Battino D, Bromley R, Kochen S, Meador K, Pennell P, Thomas SV. Management of epilepsy in pregnancy: a report from the International League Against Epilepsy Task Force on Women and Pregnancy. Epileptic Disord. 2019 Dec 1;21(6):497-517.
  226. French J.A. et al. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study // Lancet. Lancet Publishing Group, 2016. Vol. 388, № 10056. P. 2153–2163.
  227. Muthaffar OY. Neurosciences (Riyadh) Treating epilepsy with options otherthan antiepileptic medications. 2020 Aug;25(4):253-261. doi: 10.17712/nsj.2020.4.20200010.
  228. Клинические рекомендации по диагностике и лечению эпилепсии. В кн. Детская неврология. Клинические рекомендации. Выпуск1. Под редакцией В.И. Гузевой – Москва: ООО «МК»: 2014; стр.316-317.
  229. Белоусова, Е. Д. Гормональная терапия синдрома Веста / Е. Д. Белоусова, И. В. Шулякова, Т. Г. Охапкина // Журнал неврологии и психиатрии им. C.C. Корсакова. – 2016. – Т. 116. – № 9-2. – С. 61-66. – DOI 10.17116/jnevro20161169261-66
  230. Haberlandt E, Weger C, Baumgartner Sigl S, et al. Adrenocorticotropic hormone versus pulsatile dexamethasone in the treatment of infantile epilepsy syndromes. PediatrNeurol. 2010;42:21–7.
  231. К.Ю. Мухин, А.С. Петрухин. Эпилептические синдромы. Диагностика и стандарты терапии (Справочное руководство), М.; 2005; стр.75.
  232. Chiron C, Dumas C, Jambaqué I, Mumford J, Dulac O. Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis. Epilepsy Res. 1997 Jan; 26 (2): 389- 95. doi: 10.1016/s0920-1211(96)01006-6. PMID: 9095401.
  233. Silbergleit R., Durkalski V., Lowenstein D., Conwit R., Pancioli A., Palesch Y., Barsan W. for the NETT Investigators. Intramuscular versus Intravenous Therapy for Prehospital Status Epilepticus. N Engl J Med 2012; 366: 591-600 DOI: 10.1056/NEJMoa1107494.
  234. Berg A.T., Testa F.M., Levy S.R. Complete remission in nonsyndromic childhood-onset epilepsy // Ann. Neurol. Ann Neurol, 2011. Vol. 70, № 4. P. 566–573.
  235. Goellner E. et al. Timing of early and late seizure recurrence after temporal lobe epilepsy surgery // Epilepsia. Epilepsia, 2013. Vol. 54, № 11. P. 1933–1941.
  236. Lindsten H., Stenlund H., Forsgren L. Remission of seizures in a population-based adult cohort with a newly diagnosed unprovoked epileptic seizure // Epilepsia. Epilepsia, 2001. Vol. 42, № 8. P. 1025–1030.
  237. Blume W.T. et al. Glossary of descriptive terminology for ictal semiology: Report of the ILAE Task Force on classification and terminology // Epilepsia. Epilepsia, 2001. Vol. 42, № 9. P. 1212–1218.
  238. Berg A.T. et al. Revised terminology and concepts for organization of seizures and epilepsies: Report of the ILAE Commission on Classification and Terminology, 2005-2009 // Epilepsia. Epilepsia, 2010. Vol. 51, № 4. P. 676–685.
  239. Zinchuk M, Kustov G, Pashnin E, et al. Validation of the Generalized Anxiety Disorder-7 (GAD- 7) in Russian people with epilepsy. Epilepsy Behav. 2021; 123:108269.
  240. Gaspard N., Hirsch L. J., Sculier Cl., Loddenkemper T., Baalen A. van, Lancrenon J., Emmery M., Specchio N., Farias-Moeller R., Wong N., Nabbout R. New-Onset Refractory Status Epilepticus – NORSE and Febrile Infection-Related Epilepsy Syndrome –FIRES: state of the art and perspectives. Epilepsia. 2018;1–8.
  241. Prasad M, Krishnan PR, Sequeira R, Al-Roomi K. Anticonvulsant therapy for status epilepticus. Cochrane Database Syst Rev 2014; 9:CD003723. doi:10.1002/14651858.CD003723.pub3.
  242. Chamberlain JM, Okada P, Holsti M, Mahajan P, Brown KM, Vance C, Gonzalez V, Lichenstein R, Stanley R, Brousseau DC, Grubenhoff J, et al. Lorazepam vs diazepam for pediatric status epilepticus: A randomized clinical trial. JAMA. 2014;311(16):1652–60
  243. Silbergleit R, Durkalski V, Lowenstein D, Conwit R, Pancioli A, Palesch Y, Barsan W, Investigators N. Intramuscular versus intravenous therapy for prehospital status epilepticus. The New England journal of medicine. 2012;366(7):591–600 .
  244. McIntyre J, Robertson S, Norris E, Appleton R, Whitehouse WP, Phillips B, Martland T, Berry K, Collier J, Smith S, Choonara I. Safety and efficacy of buccal midazolam versus rectal diazepam for emergency treatment of seizures in children: a randomised controlled trial. Lancet. 2005;366(9481):205–10.
  245. Talukdar B, Chakrabarty B. Efficacy of buccal midazolam compared to intravenous diazepam in controlling convulsions in children: a randomized controlled trial. Brain Dev. 2009;31(10):744–9.
  246. Scott RC, Besag FM, Neville BG. Buccal midazolam and rectal diazepam for treatment of prolonged seizures in childhood and adolescence: a randomised trial. Lancet. 1999;353(9153):623–6.
  247. Mpimbaza A, Ndeezi G, Staedke S, Rosenthal PJ, Byarugaba J. Comparison of buccal midazolam with rectal diazepam in the treatment of prolonged seizures in ugandan children: a randomized clinical trial. Pediatrics. 2008;121(1):e58–64.
  248. Trinka E, Höfler J, Zerbs A, Brigo F. Efficacy and safety of intravenous valproate for status epilepticus: a systematic review. CNS Drugs 2014;28:623-639
  249. Agarwal P, Kumar N, Chandra R, Gupta G, Antony AR, Garg N. Randomized study of intravenous valproate and phenytoin in status epilepticus. Seizure. 2007;16(6):527–32
  250. Malamiri RA, Ghaempanah M, Khosroshahi N, Nikkhah A, Bavarian B, Ashrafi MR. Efficacy and safety of intravenous sodium valproate versus phenobarbital in controlling convulsive status epilepticus and acute prolonged convulsive seizures in children: a randomised trial. Eur J Paediatr Neurol. 2012;16(5):536–41.
  251. Mehta V, Singhi P, Singhi S. Intravenous sodium valproate versus diazepam infusion for the control of refractory status epilepticus in children: a randomized controlled trial. J Child Neurol. 2007;22(10):1191–7.
  252. Hubert P., Parain D., Vallee L. Management of convulsive status epilepticus in infants and children. Rev Neurol (Paris). 2009 Apr;165(4):390-7.
  253. Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: report of the guideline committee of the American Epilepsy Society. Epilepsy Curr 2016;16:48-61.
  254. Trinka Eu., Ho¨fler J., Leitinger M., Brigo F. Pharmacotherapy for Status Epilepticus Drugs (2015) 75:1499–1521.
  255. Misra UK, Kalita J, Maurya PK. Levetiracetam versus lorazepam in status epilepticus: a randomized, open labeled pilot study. J Neurol. 2012;259(4):645–8
  256. Glauser T, Shinnar S, Gloss D, Alldredge B, Arya R, Bainbridge J, et al. Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: report of the guideline committee of the American Epilepsy Society. Epilepsy Curr 2016;16:48-61.
  257. Zelano J, Kumlien E. Levetiracetam as alternative stage two antiepileptic drug in status epilepticus: a systematic review. Seizure 2012;21:233-236
  258. Kima D., Jae-Moon Kima, Yong Won Chob , Kw Ik Yangc Dong Wook Kimd , Soon-Tae Leee Young Joo Nof , Jong-Geun Seog Jung-Ick Byunh Kyung Wook Kangi Keun Tae Kimb Antiepileptic Drug Therapy for Status Epilepticus J Clin Neurol 2021;17(1):11-19.
  259. Vossler D. G., Bainbridge J. L., Boggs J. G., Novotny E. J., Loddenkemper T., Faught E., Amengual-Gual M., Fischer S. N., Gloss D. S., Olson D. M., Towne A. R., Naritoku D., Welty. T. E. Treatment of Refractory Convulsive Status Epilepticus: A Comprehensive Review by the American Epilepsy Society Treatments Committee. Epilepsy Currents 2020, Vol. 20(5) 245-264).
  260. Santamarina E, González-Cuevas M, Toledo M, Jiménez M, Becerra JL, Quílez A, et al. Intravenous lacosamide (LCM) in status epilepticus (SE): weight-adjusted dose and efficacy. Epilepsy Behav 2018;84:93-98.
  261. Ramsay RE, Sabharwal V, Khan F, Dave H, Kafai C, Shumate R, et al. Safety & pK of IV loading dose of lacosamide in the ICU. Epilepsy Behav 2015;49:340-342.
  262. Shorvon S, Baulac M, Cross H, Trinka E, Walker M; Task Force on Status Epilepticus of the ILAE Commission for European Affairs. The drug treatment of status epilepticus in Europe: consensus document from a workshop at the first London Colloquium on Status Epilepticus. Epilepsia 2008;49:1277-1285.
  263. Shorvon S, Ferlisi M. The treatment of super-refractory status epilepticus: a critical review of available therapies and a clinical treatment protocol. Brain 2011;134:2802-2818.
  264. Claassen J, Hirsch LJ, Emerson RG, Mayer SA. Treatment of refractory status epilepticus with pentobarbital, propofol, or midazolam: a systematic review. Epilepsia 2002;43:146-153.
  265. Rossetti AO, Milligan TA, Vulliémoz S, Michaelides C, Bertschi M, Lee JW. A randomized trial for the treatment of refractory status epilepticus. Neurocrit Care 2011;14:4-10.
  266. Gomes D, Pimentel J, Bentes C, Aguiar de Sousa D, Antunes AP, Alvarez A, et al. Consensus protocol for the treatment of super-refractory status epilepticus. Acta Med Port 2018;31:598-605.
  267. Fung LW, Yam KM; Yau M. LY. Ketamine use for super-refractory status epilepticus in children. Hong Kong Med J 2020 Dec;26(6):549–50.
  268. Rosati A, L"Erario M, Ilvento L, Cecchi C, Pisano T, Mirabile L, et al. Efficacy and safety of ketamine in refractory status epilepticus in children. Neurology 2012;79:2355-2358.
  269. Kramer U, Chi C-S, Lin K-L, et al. Febrile infection-related epilepsy syndrome (FIRES): pathogenesis, treatment, and outcome: a multicenter study on 77 children. Epilepsia. 2011;52:1956– 65.
  270. Hirsch LJ, Gaspard N, van Baalen A, et al. Proposed consensus definitions for new-onset refractory status epilepticus (NORSE), febrile infection-related epilepsy syndrome (FIRES), and related conditions. Epilepsia. 2018. https://doi.org/10.1111/epi.14016.
  271. Khawaja AM, DeWolfe JL, Miller DW, Szaflarski JP. New-onset refractory status epilepticus (NORSE)–the potential role for immunotherapy. Epilepsy Behav. 2015;47:17–23.
  272. Zeiler F.A., Matuszczak M., Teitebaum J., Kazina C.J., Gillman L.M.. Plasmopheresis for refractory status epilepticus Part I: a scoping systematic review of adult literature. Seizures,2016 43:14-22.
  273. Zeiler F.A., Matuszczak M., Teitebaum J., Kazina C.J., Gillman L.M. Plasmopheresis for refractory status epilepticus Part II: a scoping systematic review of pediatric literature. Seizures, 2016 43:61-68..
  274. Zeiler F A, Zeiler K J , Teitelbaum J , Gillman L M , West M. VNS for refractory status/Epilepsy Res 2015 May;112:100-13.
  275. Dibue-Adjei M, Brigo Fr., Yamamoto T., Vonck Kr., Trinka Eu.. Vagus nerve stimulation in refractory and super-refractory status epilepticus e A systematic review/ Brain Stimulation 12 (2019) 1101e1110.
  276. O"Connor SE , Ream MA, Richardson C, Mikati MA, Trescher WH, Byler DL et al. The ketogenic diet for the treatment of pediatric status epilepticus Pediatr Neurol. 2014 Jan;50(1):101-3.
  277. Lai-wah Eva Fung The ketogenic diet for the treatment of pediatric status epilepticus Pediatr Neurol. 2014 Aug;51(2):e7. doi: 10.1016/j.pediatrneurol.2014.03.016.
  278. Barkovich A.J., Guerrini R., Kuznetsk RI. et al. A developmental and genetic classification for malformations of cortical development: update 2012 // Brain. – 2012.- V.135.- P. 1348 – 1369.
  279. Pearl P.L. Inherited metabolic epilepsies: the top 10 diagnoses you cannot afford to miss. // In: Inherited metabolic epilepsies / Eds. P.L. Pearl. – 2013. – DesmosMedical, N.Y. – P.1-13.
  280. Hauser W.A. Epidemiology of epilepsy in children. // In: Eds.: J.M. Pellock, D.R. Nordli, Sankar R., Wheless J.W. / Pellock᾽s Pediatric Epilepsy. Diagnosis and their Therapy, 4th edition – DemosMedical, USA. – 2017. – P. 177 – 205.
  281. Hsu WW et al. Systematic review and meta-analysis of the efficacy and safety of perampanel in the treatment of partial-onset epilepsy. CNS Drugs. 2013 Oct; 27(10):817-27. doi: 10.1007/s40263- 013-0091-9. Erratum in: CNS Drugs. 2013 Dec;27(12):1143. PMID: 23918722; PMCID: PMC3784051.
  282. Steinhoff BJ et al. Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies. Epilepsia. 2013 Aug;54(8):1481-9. doi: 10.1111/epi.12212. Epub 2013 May 10. PMID: 23663001.
  283. O"Callaghan FJ, Edwards SW, Alber FD, Hancock E, Johnson AL, Kennedy CR, Likeman M, Lux AL, Mackay M, Mallick AA, Newton RW, Nolan M, Pressler R, Rating D, Schmitt B, Verity CM, Osborne JP; participating investigators. Safety and effectiveness of hormonal treatment versus hormonal treatment with vigabatrin for infantile spasms (ICISS): a randomised, multicentre, open- label trial. Lancet Neurol. 2017 Jan;16(1):33-42. doi: 10.1016/S1474-4422(16)30294-0. Epub 2016 Nov 10. PMID: 27838190.
  284. Chellamuthu P, Sharma S, Jain P, Kaushik JS, Seth A, Aneja S. High dose (4 mg/kg/day) versus usual dose (2 mg/kg/day) oral prednisolone for treatment of infantile spasms: an open-label, randomized controlled trial. Epilepsy Res. 2014 Oct;108(8):1378-84. doi: 10.1016/j.eplepsyres.2014.06.019. Epub 2014 Jul 5. PMID: 25048310.
  285. Gaspard N, Hirsch LJ, Sculier C, Loddenkemper T, van Baalen A, Lancrenon J, Emmery M, Specchio N, Farias-Moeller R, Wong N, Nabbout R. New-onset refractory status epilepticus (NORSE) and febrile infection-related epilepsy syndrome (FIRES): State of the art and perspectives. Epilepsia. 2018 Apr;59(4):745-752. doi: 10.1111/epi.14022. Epub 2018 Feb 24. PMID: 29476535.
  286. van Engelen B. G. M. et al. Immunoglobulin treatment in epilepsy, a review of the literature //Epilepsy research. – 1994. – Т. 19. – №. 3. – С. 181-190.
  287. Бембеева Р.Ц., Заваденко Н.Н. Внутривенные иммуноглобулины в терапии аутоиммунных заболеваний нервной системы у детей. Журнал неврологии и психиатрии им. С.С. Корсакова. 2015;115(8):83-93.
  288. Sourbron J. et al. Ketogenic diet for the treatment of pediatric epilepsy: review and meta-analysis //Child"s Nervous System. – 2020. – Т. 36. – №. 6. – С. 1099-1109.
  289. Zi-yu Zhao, Hong-ying Wang, Bin Wen, Zhi-bo Yang, Kang Feng, Jing-chun Fan. A Comparison of Midazolam, Lorazepam, and Diazepam for the Treatment of Status Epilepticus in Children: A Network Meta-analysis. Journal of Child Neurology. 2017, 1-15;
  290. Prasad M, Krishnan PR, Sequeira R, Al-Roomi K. Anticonvulsant therapy for status epilepticus. Cochrane Database of Systematic Reviews 2014, Issue 9. Art. No.: CD003723. DOI: 10.1002/14651858.CD003723.pub3).
  291. D. G. Vossler, J. L. Bainbridge, J. G. Boggs, E. J. Novotny, T. Loddenkemper, E. Faught, M. Amengual-Gual, S. N. Fischer , D. S. Gloss, D. M. Olson, A. R. Towne, D. Naritoku, T. E. Welty. Treatment of Refractory Convulsive Status Epilepticus: A Comprehensive Review by the American Epilepsy Society Treatments Committee. Epilepsy Currents 2020, Vol. 20(5) 245-264.
  292. D.G. Vossler, J.L. Bainbridge, J.G. Boggs, E.J. Novotny, T.Loddenkemper, E. Faught, M. Amengual-Gual, S.N. Fischer, D.S. Gloss, D.M. Olson, A.R. Towne, D. Naritoku, T. E. Welty. Treatment of Refractory Convulsive Status Epilepticus: A Comprehensive Review by the American Epilepsy Society Treatments Committee. Epilepsy Currents 2020, Vol. 20(5) 245-264;
  293. Daeyoung Kima , Jae-Moon Kima Yong Won Chob , Kwang Ik Yangc Dong Wook Kimd , Soon- Tae Leee Young Joo Nof , Jong-Geun Seog Jung-Ick Byunh Kyung Wook Kangi Keun Tae Kimb. Antiepileptic Drug Therapy for Status Epilepticus. J Clin Neurol 2021;17(1):11-19.
  294. Cetin Okuyaz, Kürşad Aydin, Kivilcim Gücüyener, Ayşe Serdaroğlu. Treatment of electrical status epilepticus during slow-wave sleep with high-dose corticosteroid. Pediatr Neurol. 2005 Jan;32(1):64-7; B.
  295. van den Munckhof, Al. Arzimanoglou, E. Perucca, H. C. van Teeseling, F. S. S. Leijten, K. P. J. Braun, Fl. E. Jansen. Corticosteroids versus clobazam in epileptic encephalopathy with ESES: a European multicentre randomised controlled clinical trial (RESCUE ESES*) Trials 2020 Nov 23;21(1):957.
  296. Клинические рекомендации «Алгоритмы специализированной медицинской помощи больным с сахарным диабетом»/ под ред. И.И. Дедова, М.В. Шестаковой, А.Ю Майорова. 10-й выпуск. 2021; 24(S1): С 70-71.
  297. Клинические рекомендации по сердечно-легочной реанимации у детей. Российский национальный Совет по реанимации. Объединение детских анестезиологов реаниматологов. 2014г)
  298. Shpak AA, Guekht AB, Druzhkova TA, Rider FK, Gulyaeva NV. Brain-derived neurotrophic factor in blood serum and lacrimal fluid of patients with focal epilepsy. Epilepsy Res. 2021 Oct; 176:106707. doi: 10.1016/j.eplepsyres.2021.106707. Epub 2021 Jun 29. PMID: 34225232.
  299. Международная классификация болезней (10 пересмотр). Классификация психических и поведенческих расстройств. Санкт-Петербург, 1994; 300 с.
  300. Базилевич С.Н., Прокудин М.Ю., Аверьянов Д.А., Дыскин Д.Е. Эпилептический статус: реальность 2021 // Известия Российской Военно-медицинской академии. - 2021. - Т. 40. - №4. - C. 59-68. doi: 10.17816/rmmar83623
  301. M. Ngampoopun, P. Suwanpakdee, N. Jaisupa, Ch. Nabangchang. Effectiveness and Adverse Effect of Intravenous Lacosamide in Nonconvulsive Status Epilepticus and Acute Repetitive Seizures in Children. Neurol Res Int. 2018 Jun 10;2018:8432859. doi: 10.1155/2018/8432859. eCollection 2018.
  302. Arkilo D., Gustafson M., Ritter F. J. Clinical experience of intravenous lacosamide in infants and young children. European Journal of Paediatric Neurology. 2016;20(2):212–217. doi: 10.1016/j.ejpn.2015.12.013
  303. Northam R.S., Hernandez A.W., Litzinger M.J., Minecan D.N., Glauser T.A., Mangat S., Zheng C., Souppart C., Sturm Y. Oxcarbazepine in infants and young children with partial seizures. Oxcarbazepine in infants and young children with partial seizures. Pediatr Neurol. 2005 Nov;33(5):337-44. doi: 10.1016/j.pediatrneurol.2005.05.011. PMID: 16243221.
  304. Elterman R., Glauser T.A., Wyllie E., et al, and the Topiramate YP Study Group: A double blind, randomized trial of topiramate as adjunctive therapy for partial-onset seizures in children. Neurology 1999; 52:1338–1344.
  305. de la Rosa J. S. O. et al. Efficacy of lacosamide in children and adolescents with drug-resistant epilepsy and refractory status epilepticus: A systematic review //Seizure. – 2018. – Т. 56. – С. 34-40.
  306. Yorns Jr W. R. et al. Efficacy of lacosamide as adjunctive therapy in children with refractory epilepsy //Journal of child neurology. – 2014. – Т. 29. – №. 1. – С. 23-27.
  307. Verhelst H. et al. Steroids in intractable childhood epilepsy: clinical experience and review of the literature //Seizure. – 2005. – Т. 14. – №. 6. – С. 412-421.
  308. Kurian M., Korff C. M. Steroids in pediatric epilepsy: infantile spasms and beyond //Epileptologie. – 2011. – Т. 28. – №. 1. – С. 15-20.